CUREVAC NV (CVAC) Stock Fundamental Analysis
NASDAQ:CVAC - Nasdaq - NL0015436031 - Common Stock - Currency: USD
Taking everything into account, CVAC scores 6 out of 10 in our fundamental rating. CVAC was compared to 551 industry peers in the Biotechnology industry. CVAC has an excellent financial health rating, but there are some minor concerns on its profitability. CVAC has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
CVAC had positive earnings in the past year.
CVAC had a positive operating cash flow in the past year.
CVAC had negative earnings in 4 of the past 5 years.
In multiple years CVAC reported negative operating cash flow during the last 5 years.
1.2 Ratios
With an excellent Return On Assets value of 24.34%, CVAC belongs to the best of the industry, outperforming 98.55% of the companies in the same industry.
CVAC's Return On Equity of 27.94% is amongst the best of the industry. CVAC outperforms 97.46% of its industry peers.
With an excellent Return On Invested Capital value of 24.75%, CVAC belongs to the best of the industry, outperforming 98.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.34% | ||
| ROE | 27.94% | ||
| ROIC | 24.75% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CVAC has a better Profit Margin (34.50%) than 97.46% of its industry peers.
CVAC's Operating Margin of 37.87% is amongst the best of the industry. CVAC outperforms 98.73% of its industry peers.
With an excellent Gross Margin value of 87.59%, CVAC belongs to the best of the industry, outperforming 90.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 37.87% | ||
| PM (TTM) | 34.5% | ||
| GM | 87.59% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CVAC is creating value.
CVAC has about the same amout of shares outstanding than it did 1 year ago.
CVAC has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CVAC has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 10.05 indicates that CVAC is not in any danger for bankruptcy at the moment.
The Altman-Z score of CVAC (10.05) is better than 86.21% of its industry peers.
CVAC has a debt to FCF ratio of 0.26. This is a very positive value and a sign of high solvency as it would only need 0.26 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.26, CVAC belongs to the top of the industry, outperforming 96.01% of the companies in the same industry.
A Debt/Equity ratio of 0.05 indicates that CVAC is not too dependend on debt financing.
CVAC has a Debt to Equity ratio of 0.05. This is in the lower half of the industry: CVAC underperforms 62.61% of its industry peers.
Even though the debt/equity ratio score it not favorable for CVAC, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.26 | ||
| Altman-Z | 10.05 |
ROIC/WACC3.49
WACC7.09%
2.3 Liquidity
CVAC has a Current Ratio of 7.65. This indicates that CVAC is financially healthy and has no problem in meeting its short term obligations.
CVAC's Current ratio of 7.65 is fine compared to the rest of the industry. CVAC outperforms 69.51% of its industry peers.
CVAC has a Quick Ratio of 7.64. This indicates that CVAC is financially healthy and has no problem in meeting its short term obligations.
CVAC has a Quick ratio of 7.64. This is in the better half of the industry: CVAC outperforms 69.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.65 | ||
| Quick Ratio | 7.64 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 166.39% over the past year.
CVAC shows a strong growth in Revenue. In the last year, the Revenue has grown by 787.58%.
Measured over the past years, CVAC shows a very strong growth in Revenue. The Revenue has been growing by 98.42% on average per year.
EPS 1Y (TTM)166.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.81%
Revenue 1Y (TTM)787.58%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-92.78%
3.2 Future
Based on estimates for the next years, CVAC will show a very negative growth in Earnings Per Share. The EPS will decrease by -22.50% on average per year.
The Revenue is expected to decrease by -11.04% on average over the next years. This is quite bad
EPS Next Y-165.87%
EPS Next 2Y-62.26%
EPS Next 3Y-31.61%
EPS Next 5Y-22.5%
Revenue Next Year-84.64%
Revenue Next 2Y-56.35%
Revenue Next 3Y-32.7%
Revenue Next 5Y-11.04%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 5.81 indicates a rather cheap valuation of CVAC.
Based on the Price/Earnings ratio, CVAC is valued cheaply inside the industry as 97.64% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.99. CVAC is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for CVAC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.81 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CVAC is valued cheaply inside the industry as 99.27% of the companies are valued more expensively.
98.37% of the companies in the same industry are more expensive than CVAC, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.4 | ||
| EV/EBITDA | 2.99 |
4.3 Compensation for Growth
CVAC has a very decent profitability rating, which may justify a higher PE ratio.
CVAC's earnings are expected to decrease with -31.61% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-62.26%
EPS Next 3Y-31.61%
5. Dividend
5.1 Amount
No dividends for CVAC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5.46
+0.01 (+0.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners4.7%
Inst Owner Change-3.1%
Ins Owners0.19%
Ins Owner ChangeN/A
Market Cap1.23B
Analysts72.31
Price Target4.78 (-12.45%)
Short Float %1.1%
Short Ratio0.76
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.37%
Min EPS beat(2)-18.68%
Max EPS beat(2)35.41%
EPS beat(4)2
Avg EPS beat(4)39.95%
Min EPS beat(4)-18.68%
Max EPS beat(4)161.44%
EPS beat(8)3
Avg EPS beat(8)0.33%
EPS beat(12)5
Avg EPS beat(12)-6.4%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)15.68%
Min Revenue beat(2)-86.88%
Max Revenue beat(2)118.24%
Revenue beat(4)3
Avg Revenue beat(4)139.54%
Min Revenue beat(4)-86.88%
Max Revenue beat(4)366.65%
Revenue beat(8)4
Avg Revenue beat(8)58.85%
Revenue beat(12)5
Avg Revenue beat(12)30.03%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-9.22%
PT rev (3m)-31.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)23.96%
EPS NY rev (1m)11.05%
EPS NY rev (3m)9.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)21.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.81 | ||
| Fwd PE | N/A | ||
| P/S | 2.02 | ||
| P/FCF | 7.4 | ||
| P/OCF | 6.75 | ||
| P/B | 1.64 | ||
| P/tB | 1.7 | ||
| EV/EBITDA | 2.99 |
EPS(TTM)0.94
EY17.22%
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)0.74
FCFY13.51%
OCF(TTM)0.81
OCFY14.82%
SpS2.7
BVpS3.33
TBVpS3.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 24.34% | ||
| ROE | 27.94% | ||
| ROCE | 29.12% | ||
| ROIC | 24.75% | ||
| ROICexc | 70.54% | ||
| ROICexgc | 78.69% | ||
| OM | 37.87% | ||
| PM (TTM) | 34.5% | ||
| GM | 87.59% | ||
| FCFM | 27.34% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.71
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.26 | ||
| Debt/EBITDA | 0.15 | ||
| Cap/Depr | 74.88% | ||
| Cap/Sales | 2.65% | ||
| Interest Coverage | 85.86 | ||
| Cash Conversion | 72.42% | ||
| Profit Quality | 79.25% | ||
| Current Ratio | 7.65 | ||
| Quick Ratio | 7.64 | ||
| Altman-Z | 10.05 |
F-Score8
WACC7.09%
ROIC/WACC3.49
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)166.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.81%
EPS Next Y-165.87%
EPS Next 2Y-62.26%
EPS Next 3Y-31.61%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)787.58%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-92.78%
Revenue Next Year-84.64%
Revenue Next 2Y-56.35%
Revenue Next 3Y-32.7%
Revenue Next 5Y-11.04%
EBIT growth 1Y168.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-145%
EBIT Next 3Y-28.88%
EBIT Next 5Y10.78%
FCF growth 1Y142.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y162.99%
OCF growth 3YN/A
OCF growth 5YN/A